CNS Pharmaceuticals announced a $22.5 million financing round to support its strategic pivot and pipeline development of innovative therapies addressing unmet medical needs. CEO Rami Levin highlighted how the new capital will help the company identify and advance new therapeutic assets aimed at long-term shareholder value. The company also shared its growth outlook, key milestones for investors, and plans to secure new assets to strengthen its portfolio. This positions CNS to continue developing novel treatments with potential patient benefits and shareholder returns.
Coro has formed a strategic partnership with Australian ICT distributor Leader to provide Coro's AI-powered cybersecurity platform to Leader's nationwide network of managed service providers (MSPs) and resellers. This platform simplifies security ope...
Pepeto, a new cryptocurrency project, has activated 172% APY staking during its presale, which has raised over $10.13 million in weeks. The project is led by the cofounder of the original Pepe token and supported by a Binance developer building its e...
High Arctic Overseas Holding Corp. has been appointed as the authorised sole distributor of Atlas Copco Power Technique products in Papua New Guinea. This partnership aims to introduce high-quality power generation, energy storage, mobile lighting, a...
Charlie's Holdings, a leader in premium vapor products, reported a 204% revenue increase to $4.8 million in Q1 2026 compared to Q1 2025, driven by strong sales of its SBX non-nicotine disposable vape line and new licensing for AI-powered age-gated pr...
Nanobiotix, a late-stage biotech company, announced a global follow-on offering aiming to raise approximately €75 million ($87 million). The offering includes American Depositary Shares in the U.S. and Ordinary Shares plus pre-funded warrants in Euro...
